Literature DB >> 21555309

High-sensitivity C-reactive protein is a predictor of in-hospital cardiac events in acute myocardial infarction independently of GRACE risk score.

Sergio Raposeiras-Roubín1, Cristina Barreiro Pardal, Bruno Rodiño Janeiro, Emad Abu-Assi, José María García-Acuña, José Ramón González-Juanatey.   

Abstract

High-sensitivity CRP (hsCRP) is being increasingly used as a marker for cardiac risk assessment and as a prognostic tool in acute coronary syndrome. We analyzed the relation between hsCRP values at admission and in-hospital outcomes in 98 consecutive patients with acute myocardial infarction (AMI) undergoing catheterization. Patients with cardiac events had more advanced Killip class, more proportion of depressed left ventricular ejection fraction (LVEF), higher Global Registry of Acute Coronary Events (GRACE) risk score, and higher hsCRP levels. High-sensitivity CRP and GRACE risk score showed a significant positive correlation (r = .320, P = .002). In multivariate analysis, hsCRP resulted as a predictor of worse in-hospital outcomes independently of GRACE risk score (OR 1.122, CI95%:1.005-1.252, P = .040). The hsCRP value showing the maximum likelihood ratio for predicting cardiac events was 1.45 mg/dL. High levels of hsCRP were also associated with development of contrast-induced nephropathy but not with bleeding events.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21555309     DOI: 10.1177/0003319711406502

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  7 in total

1.  Lower mean corpuscular hemoglobin concentration is associated with poorer outcomes in intensive care unit admitted patients with acute myocardial infarction.

Authors:  Yuan-Lan Huang; Zhi-De Hu
Journal:  Ann Transl Med       Date:  2016-05

2.  Study of C-reactive protein and myocardial infarction in the Indian population.

Authors:  Kavita Shalia; Sudha Savant; Vijaya A Haldankar; Tulip Nandu; Poonam Pawar; Siddhi Divekar; V K Shah; Purvi Bhatt
Journal:  Indian J Clin Biochem       Date:  2011-09-30

3.  Contrast-induced nephropathy is associated with new-onset atrial fibrillation in acute coronary syndrome after cardiac catheterization: Systemic review and meta-analysis.

Authors:  Narut Prasitlumkum; Chanavuth Kanitsoraphan; Veraprapas Kittipibul; Kittika Poonsombudlert; Nath Limpruttidham; Pattara Rattanawong; Pakawat Chongsathidkiet
Journal:  Ann Noninvasive Electrocardiol       Date:  2019-01-07       Impact factor: 1.468

4.  Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging.

Authors:  Boqia Xie; Jiaxin Wang; Xiao-Ying Xi; Xiaojuan Guo; Bi-Xi Chen; Lina Li; Cuncun Hua; Shihua Zhao; Pixiong Su; Mulei Chen; Min-Fu Yang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-05       Impact factor: 10.057

5.  Predictive value of GRACE risk scores for contrast-induced acute kidney injury in patients with ST-segment elevation myocardial infarction before undergoing primary percutaneous coronary intervention.

Authors:  Yuan Hui Liu; Yong Liu; Ning Tan; Ji-Yan Chen; Jin Chen; Shao-Hui Chen; Yi-Ting He; Peng Ran; Piao Ye; Yun Li
Journal:  Int Urol Nephrol       Date:  2013-11-22       Impact factor: 2.370

6.  The Impact of Ischemic Time on the Predictive Value of High-Sensitivity C-Reactive Protein in ST-Segment Elevation Myocardial Infarction Patients Treated by Primary Percutaneous Coronary Intervention.

Authors:  Kyung Hwan Kim; Wan Kim; Won Yu Kang; Sun Ho Hwang; Sang Cheol Cho; Weon Kim; Myung Ho Jeong
Journal:  Korean Circ J       Date:  2013-10-30       Impact factor: 3.243

7.  Fibrinogen is related to long-term mortality in Chinese patients with acute coronary syndrome but failed to enhance the prognostic value of the GRACE score.

Authors:  Yong Peng; Tian-Li Xia; Yi-Ming Li; Fang-Yang Huang; Hua Chai; Peng-Ju Wang; Wei Liu; Chen Zhang; Xiao-Bo Pu; Shi-Jian Chen; Mao Chen; De-Jia Huang
Journal:  Oncotarget       Date:  2017-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.